356: An AI experiment at the FDA & Novo trailing in the obesity drug race
The Readout Loud
00:00
Intro
This chapter examines the FDA's internal AI tool ELSA and its limitations in addressing past mistakes, alongside Novo Nordisk's challenges in the obesity drug market as it seeks to reclaim its position. Additionally, it covers major developments in biotech, including Sanofi's acquisition of Blueprint Medicines.
Transcript
Play full episode
